caprotec’s CCMS technology is a world-leading chemical proteomics technology offering significant advantages over other approaches:

These advantages put caprotec in a leading position for the purposes of target identification, toxicity deconvolution, project rescue or product re-positioning and thus CCMS is applicable in all phases of small molecule discovery and development.

Our track record shows success in identifying small molecule protein partners in species from fungi to man, and in many tissue preparations including intact cells. Our collaboration partners include some of the most prominent international pharmaceutical, biotech and agrochemical companies as well as leading academic institutions.

Partnered and in house projects include deconvolution and validation of targets from phenotypic screening, identification of protein targets causing idiosyncratic toxicities, identification of biomarkers and identification of novel protein partners, and hence alternative indications, for late stage products.

To explore how to work together with caprotec please contact We seek and find terms and conditions beneficial for all parties to our agreements. We know we can help solve our partners’ problems.